
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics is expected to have a bright future, given its unique approach to developing precision medicines for cancer by targeting individual mutations common in tumors through structure-based and computational drug design. With its lead candidate OKI-345 showing promise in PI3KαH1047R mutated breast cancer, and plans to develop product candidates against additional mutations, the company has strong potential for clinical and commercial success. The recent approval of a competitor's drug in the same market highlights the demand for effective treatments, and OnKure's preclinical data for its pan-mutant PI3Kα inhibitors OKI-345 and OKI-355 indicate they could be best-in-class, further supporting our positive outlook.
Bears say
OnKure Therapeutics is currently a risky investment with a negative outlook due to its limited financial resources and reliance on one operating segment for its revenue. Despite its focus on targeting specific drivers of underserved cancers and its drug design platform, the company has yet to generate significant revenue. Additionally, its current financial metrics, such as low cash and high debt, do not suggest a strong financial position for the company to weather any potential challenges.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares